THE BIO (더바이오)

JW Pharmaceutical partners with Tempus AI to accelerate the development of AI-driven anticancer drugs JW Pharmaceutical revealed on October 29 its plans to accelerate cancer drug development by leveraging real-world data (RWD) and organoids in collaboration with Tempus AI, a global leader in AI-driven precision medicine. The company stated that this partnership aims to swiftly validate the efficacy and safety of novel drug candidates in oncology and increase research efficiency across various cancer indications. https://lnkd.in/gcrYSgBm

JW Pharmaceutical announced on October 28 that the initial research findings demonstrating the efficacy and safety of 'Hemlibra (emicizumab)' for pediatric patients with severe hemophilia A who do not have antibodies were published in the Korean hematology journal 'BLOOD RESEARCH.’ https://lnkd.in/gUGUY4Dh

"Improving treatment landscape for frequent relapses in multiple myeloma through effective new drugs and reimbursement implementation" - J&J hosts master class on enhancing patient accessibility and latest knowledge in multiple myeloma treatment - Professor Min Chang-ki: "10% OS gap with advanced countries calls for earlier novel drug introduction and coverage applications" https://lnkd.in/gc7-7t_R

Inventage Lab chosen for the ‘Korean ARPA-H project’ to develop an ultra-fast mRNA vaccine production system for pandemic response - Consortium established among International Vaccine Institute (IVI), Catholic University of Korea, Inventage Lab, and Enzynomics - Aiming for ultra-rapid production of 1 million doses of mRNA vaccine within 100 days https://lnkd.in/gysKG6TG

Collaboration between Korea’s largest screening institute and global AC: Introducing ‘MediOpenLab’, the birthplace of precision medicine cluster ① Korea’s first private open research lab ‘Wet Lab’ launches to nurture promising bio and healthcare startups “We aim to support innovative technologies and businesses that improve the quality of life for patients and their families.” This statement reflects the mission of ‘SparkBioLabs,’ established in 2023 by SparkLabs, a global accelerator (AC), to identify and nurture promising Korean biotech and healthcare startups. SparkBioLabs is a dedicated investment firm focused on the biotechnology and healthcare sectors and launched ‘MediOpenLab,’ in April of this year in partnership with the Korea Association of Health Promotion (KAHP). This facility is Korea’s first shared laboratory managed by a medical examination institution, providing offer infrastructure to companies and startups in the medical and pharmaceutical industries while fostering growth through collaboration and innovation. will explore MediOpenLab’s role and primary business activities, highlighting the future of ‘open innovation’ that SparkLabs is pursuing in collaboration with the Korea Association of Health Promotion. https://lnkd.in/g_evD_pg

Professor Cho Byoung Chul, first author of ‘Lazertinib,’ warns: “Novel drug development is challenging under the current structure” - [Interview] Phase clinical trial (MARIPOSA) of 'Lazertinib + Rybrevant' combination therapy: first and corresponding authors revealed - Lazertinib: A journey fueled by luck and unconditional support from Yuhan Corporation's Chair of Board, Lee Jung-hee - "Collaboration between intermediary research and clinical trials is essential for creating momentum for novel drug development" https://lnkd.in/gZciVGvP

AstraZeneca Korea launches 'Lung Cancer Zero’, a public campaign to raise awareness of lung cancer early screening in non-smokers - 'Zero Lung Cancer' begins to raise public awareness to inspire change - College students take the lead in spreading the campaign’s message - The Korea Foundation for Women, the Korean Lung Cancer Patients Association, the British Embassy Seoul, and the British Chamber of Commerce in Korea will cooperate as campaign partners to foster social interest and awareness regarding the risks of lung cancer and the importance of early screening through an expanded partnership https://lnkd.in/gfwdCUuC

LaMeditech, a specialist in laser-based healthcare, announced on October 25 that it will begin full-scale entry into the U.S. market with its flagship product, the laser blood collection device 'HandyRay Series', in collaboration with the Global Procurement Development Institute. The company’s global expansion efforts commenced on the 22nd of this month when the CEO of A2A Logistics (a medical device and pharmaceutical distribution company that serves as a prime vendor for the U.S. federal government) and a sourcing expert from Kaiser Permanente (a hospital group providing comprehensive medical services) visited LaMeditech’s headquarters to test its products and discuss U.S. market entry strategies. https://lnkd.in/gfpuMRz2

Celltrion announced on October 24 that it will participate in the '2024 American College of Gastroenterology (ACG)' Conference, taking place in Pennsylvania, USA, from October 25 to 30 (local time). At the event, Celltrion will present the results of the global phase 3 clinical trial of Zymfentra, a subcutaneous injection (SC) formulation of 'Remsima', a biosimilar used to treat autoimmune diseases, highlighting its strengths. https://lnkd.in/g4gP2gZu

Daewoong Pharmaceutical announced on October 24 that at the United European Gastroenterology Week (UEGW 2024) in Vienna, Austria, held from October 12 to 15, their drug ‘Fexuclue’ garnered significant attention from global medical professionals for its ease of use and high patient satisfaction. https://lnkd.in/g5kwWrt3